Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.
J Med Genet. 2011 Feb;48(2):105-16. doi: 10.1136/jmg.2010.082552. Epub 2010 Nov 10.
Nephronophthisis associated ciliopathies (NPHP-AC) comprise a group of autosomal recessive cystic kidney diseases that includes nephronophthisis (NPHP), Senior-Loken syndrome (SLS), Joubert syndrome (JBTS), and Meckel-Gruber syndrome (MKS). To date, causative mutations in NPHP-AC have been described for 18 different genes, rendering mutation analysis tedious and expensive. To overcome the broad genetic locus heterogeneity, a strategy of DNA pooling with consecutive massively parallel resequencing (MPR) was devised.
In 120 patients with severe NPHP-AC phenotypes, five pools of genomic DNA with 24 patients each were prepared which were used as templates in order to PCR amplify all 376 exons of 18 NPHP-AC genes (NPHP1, INVS, NPHP3, NPHP4, IQCB1, CEP290, GLIS2, RPGRIP1L, NEK8, TMEM67, INPP5E, TMEM216, AHI1, ARL13B, CC2D2A, TTC21B, MKS1, and XPNPEP3). PCR products were then subjected to MPR on an Illumina Genome-Analyser and mutations were subsequently assigned to their respective mutation carrier via CEL I endonuclease based heteroduplex screening and confirmed by Sanger sequencing.
For proof of principle, DNA from patients with known mutations was used and detection of 22 out of 24 different alleles (92% sensitivity) was demonstrated. MPR led to the molecular diagnosis in 30/120 patients (25%) and 54 pathogenic mutations (27 novel) were identified in seven different NPHP-AC genes. Additionally, in 24 patients only single heterozygous variants of unknown significance were found.
The combined approach of DNA pooling followed by MPR strongly facilitates mutation analysis in broadly heterogeneous single gene disorders. The lack of mutations in 75% of patients in this cohort indicates further extensive heterogeneity in NPHP-AC.
纤毛相关的肾病(NPHP-AC)是一组常染色体隐性遗传的囊性肾病,包括肾单位肾痨病(NPHP)、Senior-Loken 综合征(SLS)、Joubert 综合征(JBTS)和 Meckel-Gruber 综合征(MKS)。迄今为止,已经在 18 个不同的基因中描述了 NPHP-AC 的致病突变,使得突变分析繁琐且昂贵。为了克服广泛的遗传基因座异质性,设计了一种 DNA 池化与连续大规模平行重测序(MPR)相结合的策略。
在 120 名具有严重 NPHP-AC 表型的患者中,制备了 5 个包含 24 名患者的基因组 DNA 池,作为模板用于 PCR 扩增 18 个 NPHP-AC 基因(NPHP1、INVS、NPHP3、NPHP4、IQCB1、CEP290、GLIS2、RPGRIP1L、NEK8、TMEM67、INPP5E、TMEM216、AHI1、ARL13B、CC2D2A、TTC21B、MKS1 和 XPNPEP3)的所有 376 个外显子。然后将 PCR 产物进行 Illumina 基因组分析仪上的 MPR,并通过 CEL I 内切酶基于异源双链筛选将突变分配给各自的突变携带者,并通过 Sanger 测序进行确认。
作为原理验证,使用了已知突变患者的 DNA,证明了 24 个不同等位基因中的 22 个(92%的灵敏度)的检测。MPR 在 120 名患者中的 30 名(25%)中导致了分子诊断,并在七个不同的 NPHP-AC 基因中发现了 54 个致病性突变(27 个新突变)。此外,在 24 名患者中,仅发现了单个杂合的意义不明的变异。
DNA 池化后进行 MPR 的联合方法极大地促进了广泛异质性单基因疾病的突变分析。在该队列的 75%的患者中未发现突变表明 NPHP-AC 存在进一步的广泛异质性。